DE60138955D1 - Xanthin-phosphodiesteras-v-inhibitoren - Google Patents

Xanthin-phosphodiesteras-v-inhibitoren

Info

Publication number: DE60138955D1
Authority: DE; Germany
Prior art keywords: phosphodiesteras; inhibitoren; xanthin
Prior art date: 2000-09-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60138955T

Other languages

English (en)

Inventor

Samuel Chackalamannil

Yuguang Wang

Craig D Boyle

Andrew W Stamford

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-19

Filing date

2001-09-17

Publication date

2009-07-23

2001-09-17 Application filed by Schering Corp filed Critical Schering Corp

2009-07-23 Application granted granted Critical

2009-07-23 Publication of DE60138955D1 publication Critical patent/DE60138955D1/de

2021-09-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DE60138955T 2000-09-19 2001-09-17 Xanthin-phosphodiesteras-v-inhibitoren Expired - Lifetime DE60138955D1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23356700P	2000-09-19	2000-09-19
PCT/US2001/028983 WO2002024698A1 (en)	2000-09-19	2001-09-17	Xanthine phosphodiesterase v inhibitors

Publications (1)

Publication Number	Publication Date
DE60138955D1 true DE60138955D1 (en)	2009-07-23

Family

ID=22877764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60138955T Expired - Lifetime DE60138955D1 (en)	2000-09-19	2001-09-17	Xanthin-phosphodiesteras-v-inhibitoren

Country Status (29)

Country	Link
US (6)	US6821978B2 (de)
EP (1)	EP1319003B1 (de)
JP (2)	JP4015547B2 (de)
KR (1)	KR100610417B1 (de)
CN (1)	CN1252071C (de)
AR (1)	AR035199A1 (de)
AT (1)	ATE433451T1 (de)
AU (2)	AU9102201A (de)
BR (1)	BR0113953A (de)
CA (1)	CA2421910C (de)
CY (1)	CY1109329T1 (de)
DE (1)	DE60138955D1 (de)
DK (1)	DK1319003T3 (de)
EC (1)	ECSP034519A (de)
ES (1)	ES2326956T3 (de)
HU (1)	HUP0303016A3 (de)
IL (1)	IL154839A0 (de)
MX (1)	MXPA03002361A (de)
NO (1)	NO328753B1 (de)
NZ (1)	NZ524433A (de)
PE (1)	PE20020469A1 (de)
PL (1)	PL205188B1 (de)
PT (1)	PT1319003E (de)
RU (1)	RU2302420C9 (de)
SI (1)	SI1319003T1 (de)
SK (1)	SK3192003A3 (de)
TW (1)	TWI241301B (de)
WO (1)	WO2002024698A1 (de)
ZA (1)	ZA200301863B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
DE50209483D1 (de) *	2001-02-24	2007-03-29	Boehringer Ingelheim Pharma	Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ES2185606T3 (es) *	2001-03-21	2003-05-01	Sanol Arznei Schwarz Gmbh	Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
WO2003004496A1 (en) *	2001-07-03	2003-01-16	Novo Nordisk A/S	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2005509603A (ja) *	2001-09-19	2005-04-14	ノボ　ノルディスク　アクティーゼルスカブ	Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
WO2003042216A1 (en) *	2001-11-09	2003-05-22	Schering Corporation	Polycyclic guanine derivative phosphodiesterase v inhibitors
CA2470210A1 (en) *	2001-12-17	2003-06-26	Altana Pharma Ag	Use of selective pde5 inhibitors for treating partial and global respiratory failure
US20030181461A1 (en) *	2002-01-25	2003-09-25	Lautt Wilfred Wayne	Use of phosphodiesterase antagonists to treat insulin resistance
MXPA04011862A (es) *	2002-05-31	2005-03-31	Schering Corp	Procedimiento para preparar inhibidores xantina de la fosfodiesterasa v, y precursores de los mismos.
SI1509525T1 (sl)	2002-05-31	2006-12-31	Schering Corp	Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
ES2299720T3 (es) *	2002-05-31	2008-06-01	Schering Corporation	Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v.
US7495004B2 (en) *	2002-06-17	2009-02-24	Glaxo Group Limited	Purine derivatives as liver X receptor agonists
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) *	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en)	2002-08-22	2009-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en)	2003-06-18	2009-07-28	Boehringer Ingelheim International Gmbh	Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE602004006756T2 (de) *	2003-07-31	2008-01-24	Schering Corp.	Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
JPWO2005021550A1 (ja) *	2003-08-29	2006-10-26	大日本住友製薬株式会社	二環性ピラゾール誘導体
JP2007512345A (ja) *	2003-11-21	2007-05-17	シェーリング　コーポレイション	ホスホジエステラーゼｖ阻害剤処方物
DE10355304A1 (de)	2003-11-27	2005-06-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7794987B2 (en) *	2003-12-02	2010-09-14	Ucb Pharma Gmbh	Method for treating central neuropathic pain
WO2005077950A2 (en)	2004-02-14	2005-08-25	Smithkline Beecham Corporation	Medicaments with hm74a receptor activity
US7501426B2 (en) *	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) *	2004-02-23	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) *	2004-03-13	2008-07-01	Boehringer Ingleheim International Gmbh	Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20070042969A1 (en) *	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) *	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
US7179809B2 (en) *	2004-04-10	2007-02-20	Boehringer Ingelheim International Gmbh	2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en)	2004-05-10	2008-10-21	Boehringer Ingelheim International Gmbh	Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
AU2005249794A1 (en)	2004-06-04	2005-12-15	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical composition containing irbesartan
EP1604655A1 (de) *	2004-06-09	2005-12-14	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
DE102004030502A1 (de) *	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) *	2004-09-11	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) *	2004-09-14	2006-03-16	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101102775A (zh) *	2004-11-18	2008-01-09	先灵公司	采用pdev抑制剂治疗充血性心衰的方法
US20070004745A1 (en) *	2005-03-25	2007-01-04	Schering-Plough Corporation	Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
PT2366393E (pt)	2005-04-19	2013-10-04	Takeda Gmbh	Roflumilaste para o tratamento da hipertensão pulmonar
CA2612917A1 (en) *	2005-06-23	2007-01-04	Schering Corporation	Rapidly absorbing oral formulations of pde5 inhibitors
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ATE487719T1 (de) *	2005-08-10	2010-11-15	Glaxosmithkline Llc	Xanthinderivate als selektive hm74a-agonisten
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
EP1754476A1 (de) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US9012454B2 (en)	2005-12-09	2015-04-21	Mayo Foundation For Medical Education And Research	Sexual dysfunction
SG174054A1 (en)	2006-05-04	2011-09-29	Boehringer Ingelheim Int	Polymorphs
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (de) *	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
TWI397417B (zh)	2006-06-15	2013-06-01	Ucb Pharma Gmbh	具有協同抗驚厥功效之醫藥組成物
EP2057160A1 (de)	2006-08-08	2009-05-13	Boehringer Ingelheim International GmbH	Pyrrolo[3,2-d]pyrimidine als dpp-iv-inhibitoren zur behandlung von diabetes mellitus
WO2008125388A1 (en) *	2007-04-17	2008-10-23	Ratiopharm Gmbh	Pharmaceutical compositions comprising irbesartan
RU2344137C1 (ru) *	2007-07-18	2009-01-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА)	Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
ES2733348T3 (es) *	2007-08-17	2019-11-28	Boehringer Ingelheim Int	Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EP2326326B1 (de) *	2008-08-15	2019-10-09	Boehringer Ingelheim International GmbH	Dpp-4 inhibitoren zur verwendung in der wundheilung von diabetes-patienten
EP2344195A2 (de)	2008-09-10	2011-07-20	Boehringer Ingelheim International GmbH	Kombinationstherapie zur behandlung von diabetes und zugehörigen leiden
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010072776A1 (en)	2008-12-23	2010-07-01	Boehringer Ingelheim International Gmbh	Salt forms of organic compound
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es)	2010-05-05	2016-08-04	Boehringer Ingelheim Int Gmbh *	Terapia de combinacion.
KR20230051307A (ko)	2010-06-24	2023-04-17	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en)	2011-07-15	2019-04-23	Boehringer Ingelheim Int	SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US20130303462A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN105796569A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
JP6615109B2 (ja)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
BR112018072401A2 (pt)	2016-06-10	2019-02-19	Boehringer Ingelheim International Gmbh	combinações de linagliptina e metformina
AU2019287546A1 (en) *	2018-06-14	2021-01-21	Astrazeneca Uk Limited	Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CN110613717A (zh) *	2019-05-17	2019-12-27	中国医学科学院医药生物技术研究所	一种降低血脂的药物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1938016A1 (de)	1969-07-23	1971-01-28	Fischer Ohg Arzneimittelwerk	Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten
FR2116302A1 (en)	1970-12-07	1972-07-13	Brun Lab Sa Le	8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity
ES2033922T3 (es)	1986-08-28	1993-04-01	Sandoz Ag	Procedimiento para preparar nuevos derivados de xantina.
IT1217190B (it)	1988-04-22	1990-03-14	Recordati Chem Pharm	Composti utili per il trattamento e diagnosi di disfunzioni frettili
US5321029A (en)	1988-11-14	1994-06-14	Beecham-Wuelfing Gmbh & Co.K.G.	Xanthines
GB8906792D0 (en)	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
FR2654935B1 (fr)	1989-11-28	1994-07-01	Lvmh Rech	Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
NZ238609A (en)	1990-06-21	1993-12-23	Schering Corp	Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
GB9020921D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
GB9020959D0 (en)	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
DE69132291T2 (de)	1990-12-21	2000-12-14	Beecham Group P.L.C., Brentford	Xanthinderivate
US5688768A (en)	1991-02-19	1997-11-18	Cor Therapeutics, Inc.	Recombinant thrombin receptor and related pharmaceuticals
US5256766A (en)	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9210839D0 (en)	1992-05-21	1992-07-08	Smithkline Beecham Plc	Novel compounds
TW252044B (de) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
GB9226532D0 (en)	1992-12-21	1993-02-17	Smithkline Beecham Plc	Compounds
HUT72640A (en)	1993-02-26	1996-05-28	Schering Corp	2-benzyl-polycyclic guanine derivatives, pharmaceutical compositions containing them and process for preparing them
GB9311920D0 (en)	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
US6143746A (en)	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US6069156A (en)	1995-04-10	2000-05-30	Fujisawa Pharmaceutical Co., Ltd.	Indole derivatives as cGMP-PDE inhibitors
US5731339A (en)	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
GB9514464D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5824683A (en)	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
AU722514B2 (en)	1995-12-28	2000-08-03	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
KR20000010918A (ko)	1996-05-10	2000-02-25	게리 엘. 윌콕스	카르볼린 유도체
GB9612514D0 (en)	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
EP0863144A4 (de)	1996-08-30	2001-04-11	Kyowa Hakko Kogyo Kk	Imidazochinazoline
AU4400597A (en)	1996-10-08	1998-05-05	Fujisawa Pharmaceutical Co., Ltd.	Indole derivatives
US5958926A (en)	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5874437A (en)	1996-11-01	1999-02-23	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998038168A1 (en)	1997-02-27	1998-09-03	Tanabe Seiyaku Co., Ltd.	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
EP0977756A1 (de)	1997-04-25	2000-02-09	Pfizer Limited	Pyrazolopyrimidinone, die den typ 5 der cyclischen guanosin 3',5'-monophosphat phospodiesterase (cgmp pde5) hemmen, zur behandlung von sexuellen funktionsstörungen
US6027494A (en) *	1997-06-06	2000-02-22	Autonomous Technologies Corporation	Ablatement designed for dark adaptability
TW453999B (en)	1997-06-27	2001-09-11	Fujisawa Pharmaceutical Co	Benzimidazole derivatives
WO1999000359A1 (fr)	1997-06-27	1999-01-07	Fujisawa Pharmaceutical Co., Ltd.	Derives de noyau aromatique
WO1999021831A1 (en)	1997-10-27	1999-05-06	Fujisawa Pharmaceutical Co., Ltd.	Tricyclic compounds as cgmp-pde inhibitors
US6403597B1 (en)	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US5877216A (en)	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
EP1027057A4 (de)	1997-10-28	2003-01-02	Vivus Inc	Behandlung von weibliche sexuelle störungen
US6037346A (en)	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU734734B2 (en)	1997-10-28	2001-06-21	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CH693954A5 (de)	1997-11-12	2004-05-14	Bayer Ag	2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase Inhibitoren.
HUP0003219A3 (en)	1998-02-19	2001-07-30	Eisai Co Ltd	Phthalazine derivatives, process for producing them and pharmaceutical compositions containing them and use of the compounds for producing pharmaceutical compositions useful for treating erectile dysfunction
AU2641099A (en)	1998-02-27	1999-09-15	Kyowa Hakko Kogyo Co. Ltd.	Imidazoquinazoline derivatives
WO1999043674A1 (fr)	1998-02-27	1999-09-02	Kyowa Hakko Kogyo Co., Ltd.	Remedes contre les dysfonctionnements de l'erection
DE19816857A1 (de)	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL343794A1 (en)	1998-04-20	2001-09-10	Pfizer	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AU4501199A (en)	1998-06-03	1999-12-20	Almirall Prodesfarma S.A.	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087362A (en)	1999-03-16	2000-07-11	Pentech Pharmaceuticals, Inc.	Apomorphine and sildenafil composition
US6023640A (en)	1999-03-29	2000-02-08	Ross; Jesse	Method contributing to obviating male impotency
CO5271697A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
DE50209483D1 (de) *	2001-02-24	2007-03-29	Boehringer Ingelheim Pharma	Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
JP2005509603A (ja) *	2001-09-19	2005-04-14	ノボ　ノルディスク　アクティーゼルスカブ	Ｄｐｐ−ｉｖ酵素の阻害剤であるヘテロ環化合物
DE60323823D1 (de) *	2002-01-11	2008-11-13	Novo Nordisk As	Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
MXPA04011862A (es) *	2002-05-31	2005-03-31	Schering Corp	Procedimiento para preparar inhibidores xantina de la fosfodiesterasa v, y precursores de los mismos.
ES2299720T3 (es) *	2002-05-31	2008-06-01	Schering Corporation	Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v.
DE602004006756T2 (de) *	2003-07-31	2008-01-24	Schering Corp.	Metabolite eines xanthinphosphodiesterase-5-inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen

2001
- 2001-08-28 US US09/940,760 patent/US6821978B2/en not_active Expired - Fee Related
- 2001-09-17 DK DK01971092T patent/DK1319003T3/da active
- 2001-09-17 AU AU9102201A patent/AU9102201A/xx active Pending
- 2001-09-17 SI SI200130934T patent/SI1319003T1/sl unknown
- 2001-09-17 CN CNB018159125A patent/CN1252071C/zh not_active Expired - Fee Related
- 2001-09-17 AU AU2001291022A patent/AU2001291022B2/en not_active Ceased
- 2001-09-17 CA CA002421910A patent/CA2421910C/en not_active Expired - Fee Related
- 2001-09-17 PL PL361729A patent/PL205188B1/pl not_active IP Right Cessation
- 2001-09-17 JP JP2002529108A patent/JP4015547B2/ja not_active Expired - Fee Related
- 2001-09-17 HU HU0303016A patent/HUP0303016A3/hu unknown
- 2001-09-17 AT AT01971092T patent/ATE433451T1/de active
- 2001-09-17 NZ NZ524433A patent/NZ524433A/en not_active IP Right Cessation
- 2001-09-17 DE DE60138955T patent/DE60138955D1/de not_active Expired - Lifetime
- 2001-09-17 PT PT01971092T patent/PT1319003E/pt unknown
- 2001-09-17 SK SK319-2003A patent/SK3192003A3/sk unknown
- 2001-09-17 WO PCT/US2001/028983 patent/WO2002024698A1/en active Application Filing
- 2001-09-17 ES ES01971092T patent/ES2326956T3/es not_active Expired - Lifetime
- 2001-09-17 BR BR0113953-3A patent/BR0113953A/pt not_active Application Discontinuation
- 2001-09-17 MX MXPA03002361A patent/MXPA03002361A/es active IP Right Grant
- 2001-09-17 RU RU2003111460/04A patent/RU2302420C9/ru not_active IP Right Cessation
- 2001-09-17 EP EP01971092A patent/EP1319003B1/de not_active Expired - Lifetime
- 2001-09-17 IL IL15483901A patent/IL154839A0/xx unknown
- 2001-09-17 KR KR1020037003898A patent/KR100610417B1/ko not_active Expired - Fee Related
- 2001-09-18 AR ARP010104405A patent/AR035199A1/es active IP Right Grant
- 2001-09-18 PE PE2001000936A patent/PE20020469A1/es not_active Application Discontinuation
- 2001-09-19 TW TW090123426A patent/TWI241301B/zh not_active IP Right Cessation
2003
- 2003-03-06 ZA ZA200301863A patent/ZA200301863B/en unknown
- 2003-03-18 NO NO20031238A patent/NO328753B1/no not_active IP Right Cessation
- 2003-03-19 EC EC2003004519A patent/ECSP034519A/es unknown
2004
- 2004-02-12 US US10/777,849 patent/US7268141B2/en not_active Expired - Fee Related
- 2004-06-09 US US10/864,218 patent/US20040229885A1/en not_active Abandoned
- 2004-11-16 US US10/990,083 patent/US20050075349A1/en not_active Abandoned
2005
- 2005-03-11 US US11/078,999 patent/US20050182077A1/en not_active Abandoned
2007
- 2007-08-02 JP JP2007202402A patent/JP2007297409A/ja not_active Withdrawn
- 2007-09-10 US US11/852,638 patent/US7531544B2/en not_active Expired - Fee Related
2009
- 2009-08-24 CY CY20091100890T patent/CY1109329T1/el unknown

Also Published As

Publication number	Publication date
HK1056550A1 (en)	2004-02-20
KR20030036800A (ko)	2003-05-09
CY1109329T1 (el)	2014-07-02
ECSP034519A (es)	2003-04-25
US7531544B2 (en)	2009-05-12
JP4015547B2 (ja)	2007-11-28
CN1460105A (zh)	2003-12-03
US20040167137A1 (en)	2004-08-26
PL205188B1 (pl)	2010-03-31
PE20020469A1 (es)	2002-06-18
AU9102201A (en)	2002-04-02
US7268141B2 (en)	2007-09-11
KR100610417B1 (ko)	2006-08-08
US6821978B2 (en)	2004-11-23
SI1319003T1 (sl)	2009-10-31
US20080058354A1 (en)	2008-03-06
NZ524433A (en)	2004-09-24
EP1319003A1 (de)	2003-06-18
IL154839A0 (en)	2003-10-31
CA2421910A1 (en)	2002-03-28
PT1319003E (pt)	2009-07-23
HUP0303016A2 (hu)	2003-12-29
DK1319003T3 (da)	2009-09-28
AR035199A1 (es)	2004-05-05
TWI241301B (en)	2005-10-11
US20050182077A1 (en)	2005-08-18
NO20031238D0 (no)	2003-03-18
ES2326956T3 (es)	2009-10-22
US20040229885A1 (en)	2004-11-18
WO2002024698A1 (en)	2002-03-28
MXPA03002361A (es)	2003-06-30
HUP0303016A3 (en)	2007-03-28
US20020169174A1 (en)	2002-11-14
NO328753B1 (no)	2010-05-03
ZA200301863B (en)	2004-06-22
SK3192003A3 (en)	2003-08-05
US20050075349A1 (en)	2005-04-07
EP1319003B1 (de)	2009-06-10
CN1252071C (zh)	2006-04-19
AU2001291022B2 (en)	2007-01-18
RU2302420C9 (ru)	2008-12-10
RU2302420C2 (ru)	2007-07-10
JP2007297409A (ja)	2007-11-15
CA2421910C (en)	2007-07-10
PL361729A1 (en)	2004-10-04
JP2004509892A (ja)	2004-04-02
NO20031238L (no)	2003-05-14
ATE433451T1 (de)	2009-06-15
BR0113953A (pt)	2003-07-22

Publication	Publication Date	Title
DE60105852D1 (en)	2004-10-28	Fluidmischsystem
DE60138955D1 (en)	2009-07-23	Xanthin-phosphodiesteras-v-inhibitoren
DE50112082D1 (en)	2007-04-05	Bulk-acoustic-wave-filter
DE60115644D1 (en)	2006-01-12	Thiazinoxazolidinon
DE60121590D1 (en)	2006-08-31	Pyrazolderivate
DE50104081D1 (en)	2004-11-18	Hydrolager
AU3391801A (en)	2001-09-03	Pyridinylimidazoles
DE60128102D1 (en)	2007-06-06	Imidazolderivate
AU8274301A (en)	2002-02-18	Electro-powder
DE60114954D1 (en)	2005-12-22	Polytrimethylenterephthalatgarn
AU6803901A (en)	2002-01-02	Bis-arylsulfones
DE50112740D1 (en)	2007-08-30	Strangführungselement
DE50110569D1 (en)	2006-09-07	Substituierte c-cyclohexylmethylamin-derivate
DE60120222D1 (en)	2006-07-06	Laser-anemometer
DE50102859D1 (en)	2004-08-19	Hochfliessfähige propylenblockcopolymerisate
DE50107376D1 (en)	2005-10-13	Orientierte acrylathotmelts
DE50112014D1 (en)	2007-03-22	Stiftheizer
AU9385201A (en)	2002-04-22	Sulfonylguanidine
AU6619001A (en)	2002-01-08	Liquid-pourers
DE50008626D1 (en)	2004-12-16	Substituierte aminomethyl-phenyl-cyclohexanderivate
DE60114837D1 (en)	2005-12-15	Signalmessung
DE50114303D1 (en)	2008-10-23	Nsaugluftkanal
DE50008447D1 (en)	2004-12-02	Aminomethyl-phenyl-cyclohexanonderivate
DE50114375D1 (en)	2008-11-13	Compound-reibungsvakuumpumpe
AU4686401A (en)	2001-10-23	Hypotensors

Legal Events

Date	Code	Title	Description
2010-07-01	8364	No opposition during term of opposition